Search Results : Alzheimer

556 interactions found:

Sort by: Relevance Number of Pathways Number of Drugs Number of Diseases
Novel Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
CDK2 and PAX2
Name 1
cyclin dependent kinase 2
Name2
paired box 2
Pathway 1
  • G0 and Early G1
  • Telomere Extension By Telomerase
  • Activation of ATR in response to replication stress
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Processing of DNA double-strand break ends
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • G2 Phase
  • Orc1 removal from chromatin
  • Activation of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates Cell Cycle
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Factors involved in megakaryocyte development and platelet production
Pathway 2
  • Formation of intermediate mesoderm
  • Formation of the nephric duct
  • Formation of the ureteric bud
Drugs 1
  • 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
  • Staurosporine
  • Indirubin-3'-monoxime
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
  • Olomoucine
  • 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide
  • 2-Amino-6-Chloropyrazine
  • 6-O-Cyclohexylmethyl Guanine
  • N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide
  • 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
  • N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
  • Purvalanol
  • [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
  • (5R)-5-{[(2-Amino-3H-purin-6-yl)oxy]methyl}-2-pyrrolidinone
  • 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine
  • Hymenialdisine
  • (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine
  • 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide
  • 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
  • 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
  • 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
  • SU9516
  • 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
  • Alvocidib
  • (2E,3S)-3-hydroxy-5'-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-methyl-1,3-dihydro-2,3'-biindol-2'(1'H)-one
  • 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol
  • 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One
  • Lysine Nz-Carboxylic Acid
  • [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone
  • N'-[4-(2,4-Dimethyl-1,3-thiazol-5-yl)-2-pyrimidinyl]-N-hydroxyimidoformamide
  • N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea
  • 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
  • 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
  • OLOMOUCINE II
  • TRIAZOLOPYRIMIDINE
  • Seliciclib
  • Bosutinib
  • 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
  • (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
  • N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
  • 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
  • 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
  • (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
  • 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE
  • (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine
  • O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE
  • (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide
  • 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
  • N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
  • 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
  • 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
  • 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE
  • (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
  • 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
  • 5-Bromoindirubin
  • (2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (5E)-2-Amino-5-(2-pyridinylmethylene)-1,3-thiazol-4(5H)-one
  • 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
  • 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE
  • N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE
  • (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE
  • 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
  • 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
  • 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE
  • 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA
  • 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • CAN-508
  • (2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE
  • 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
  • (2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol
  • N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
  • 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • RO-4584820
  • N-Methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide
  • N-methyl-{4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide
  • 3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one
  • 4-{[(2-Oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}-N-(1,3-thiazol-2-yl)benzenesulfonamide
  • 3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1H-indole
  • 5-hydroxynaphthalene-1-sulfonamide
  • N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
  • 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
  • N-phenyl-1H-pyrazole-3-carboxamide
  • 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide
  • {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
  • 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE
  • 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide
  • AT-7519
  • 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
  • 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine
  • 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE
  • 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
  • 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE
  • 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
  • (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
  • 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
  • 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE
  • 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE
  • (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
  • 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine
  • 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine
  • N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine
  • 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
  • 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
  • N-(5-Isopropyl-thiazol-2-YL)-2-pyridin-3-YL-acetamide
  • Variolin B
  • N(6)-dimethylallyladenine
  • Trilaciclib
Drugs 2
Diseases 1
Diseases 2
  • Renal coloboma syndrome (RCS); Papillorenal syndrome
Novel
Novel
Symbols
BYSL and ETF1
Name 1
bystin like
Name2
eukaryotic translation termination factor 1
Pathway 1
  • Major pathway of rRNA processing in the nucleolus and cytosol
Pathway 2
  • Eukaryotic Translation Termination
  • Eukaryotic Translation Termination
  • Regulation of expression of SLITs and ROBOs
  • Protein hydroxylation
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
CDH1 and CDH5
Name 1
cadherin 1
Name2
cadherin 5
Pathway 1
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Integrin cell surface interactions
  • Apoptotic cleavage of cell adhesion proteins
  • Adherens junctions interactions
  • RHO GTPases activate IQGAPs
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of CDH1 Function
  • Regulation of CDH1 mRNA translation by microRNAs
  • Degradation of CDH1
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Formation of definitive endoderm
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Developmental Lineage of Mammary Stem Cells
Pathway 2
  • Adherens junctions interactions
  • VEGFR2 mediated vascular permeability
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
Drugs 1
Drugs 2
  • Lenalidomide
  • FX06
Diseases 1
  • Penile cancer
  • Breast cancer
  • Gastric cancer
  • Nasopharyngeal cancer
  • Hepatocellular carcinoma
  • Thyroid cancer
Diseases 2
Novel
Novel
Symbols
CENPF and IRF6
Name 1
centromere protein F
Name2
interferon regulatory factor 6
Pathway 1
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Polo-like kinase mediated events
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • EML4 and NUDC in mitotic spindle formation
Pathway 2
  • Interferon gamma signaling
  • Interferon alpha/beta signaling
Drugs 1
Drugs 2
Diseases 1
Diseases 2
  • IRF6-related disorders, including: Popliteal pterygium syndrome (PPS); Van der Woude syndrome (VWS)
  • Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
Novel
Novel
Symbols
FXR1 and SERINC5
Name 1
FMR1 autosomal homolog 1
Name2
serine incorporator 5
Pathway 1
  • Signaling by BRAF and RAF1 fusions
Pathway 2
  • Serine metabolism
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
HDAC2 and TREML2
Name 1
histone deacetylase 2
Name2
triggering receptor expressed on myeloid cells like 2
Pathway 1
  • p75NTR negatively regulates cell cycle via SC1
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • HDACs deacetylate histones
  • Notch-HLH transcription pathway
  • ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
  • NoRC negatively regulates rRNA expression
  • SUMOylation of chromatin organization proteins
  • Regulation of TP53 Activity through Acetylation
  • RNA Polymerase I Transcription Initiation
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Regulation of MECP2 expression and activity
  • MECP2 regulates neuronal receptors and channels
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • EGR2 and SOX10-mediated initiation of Schwann cell myelination
  • EGR2 and SOX10-mediated initiation of Schwann cell myelination
  • Potential therapeutics for SARS
  • STAT3 nuclear events downstream of ALK signaling
  • Negative Regulation of CDH1 Gene Transcription
  • Factors involved in megakaryocyte development and platelet production
  • Regulation of endogenous retroelements by KRAB-ZFP proteins
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
  • Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)
Pathway 2
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Drugs 1
  • Pravastatin
  • Lovastatin
  • Theophylline
  • Valproic acid
  • Valproic acid
  • Simvastatin
  • Atorvastatin
  • Fluvastatin
  • Aminophylline
  • Decitabine
  • Oxtriphylline
  • Vorinostat
  • Vorinostat
  • Belinostat
  • Pracinostat
  • Romidepsin
  • Romidepsin
  • Panobinostat
  • Phenylbutyric acid
  • Tixocortol
  • Mocetinostat
  • Entinostat
  • Abexinostat
  • Givinostat
  • Pyroxamide
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
FGFR3 and STK32B
Name 1
fibroblast growth factor receptor 3
Name2
serine/threonine kinase 32B
Pathway 1
  • Signaling by activated point mutants of FGFR3
  • t(4;14) translocations of FGFR3
  • Signaling by FGFR3 in disease
  • Signaling by FGFR3 fusions in cancer
Pathway 2
Drugs 1
  • XL999
  • Pazopanib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Infigratinib
  • Fostamatinib
  • Erdafitinib
  • Pemigatinib
  • Futibatinib
  • Selpercatinib
Drugs 2
Diseases 1
  • CATSHL syndrome
  • Multiple myeloma
  • FGFR3-related short limb skeletal dysplasias, including: Achondroplasia; Hypochondroplasia; Thanatophoric dysplasia, type 1; Thanatophoric dysplasia, type 2; Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN)
  • Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome
  • Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
  • Bladder cancer
Diseases 2
Novel
Novel
Symbols
CEBPG and CYP26B1
Name 1
CCAAT enhancer binding protein gamma
Name2
cytochrome P450 family 26 subfamily B member 1
Pathway 1
  • ATF4 activates genes in response to endoplasmic reticulum stress
  • Response of EIF2AK4 (GCN2) to amino acid deficiency
  • Response of EIF2AK1 (HRI) to heme deficiency
Pathway 2
  • Vitamins
  • RA biosynthesis pathway
  • Defective CYP26B1 causes RHFCA
Drugs 1
Drugs 2
  • Tretinoin
Diseases 1
Diseases 2
Novel
Novel
Symbols
POLR2L and ACSL6
Name 1
RNA polymerase II, I and III subunit L
Name2
acyl-CoA synthetase long chain family member 6
Pathway 1
  • Formation of RNA Pol II elongation complex
  • Formation of the Early Elongation Complex
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Pausing and recovery of Tat-mediated HIV elongation
  • Abortive elongation of HIV-1 transcript in the absence of Tat
  • Tat-mediated HIV elongation arrest and recovery
  • Tat-mediated elongation of the HIV-1 transcript
  • HIV elongation arrest and recovery
  • Pausing and recovery of HIV elongation
  • Viral Messenger RNA Synthesis
  • Cytosolic sensors of pathogen-associated DNA
  • MicroRNA (miRNA) biogenesis
  • NoRC negatively regulates rRNA expression
  • B-WICH complex positively regulates rRNA expression
  • Transcriptional regulation by small RNAs
  • PIWI-interacting RNA (piRNA) biogenesis
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • RNA Polymerase II Pre-transcription Events
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of DNA Repair Genes
  • FGFR2 alternative splicing
  • RNA polymerase II transcribes snRNA genes
  • RNA polymerase II transcribes snRNA genes
  • mRNA Capping
  • mRNA Splicing - Major Pathway
  • mRNA Splicing - Minor Pathway
  • Processing of Capped Intron-Containing Pre-mRNA
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase III Chain Elongation
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase III Transcription Termination
  • RNA Polymerase III Abortive And Retractive Initiation
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Elongation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Polymerase III Transcription Initiation From Type 1 Promoter
  • RNA Polymerase III Transcription Initiation From Type 1 Promoter
  • RNA Polymerase III Transcription Initiation From Type 2 Promoter
  • RNA Polymerase III Transcription Initiation From Type 2 Promoter
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • RNA Pol II CTD phosphorylation and interaction with CE
  • Signaling by FGFR2 IIIa TM
  • Estrogen-dependent gene expression
  • Inhibition of DNA recombination at telomere
Pathway 2
  • Synthesis of very long-chain fatty acyl-CoAs
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
DTNBP1 and BLOC1S3
Name 1
dystrobrevin binding protein 1
Name2
biogenesis of lysosomal organelles complex 1 subunit 3
Pathway 1
  • Golgi Associated Vesicle Biogenesis
Pathway 2
  • Golgi Associated Vesicle Biogenesis
Drugs 1
Drugs 2
Diseases 1
  • Hermansky-Pudlak syndrome (HPS)
Diseases 2
  • Hermansky-Pudlak syndrome (HPS)
Novel
Novel
Symbols
ACAN and SLCO3A1
Name 1
aggrecan
Name2
solute carrier organic anion transporter family member 3A1
Pathway 1
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Keratan sulfate biosynthesis
  • Keratan sulfate degradation
  • ECM proteoglycans
  • Defective CHST6 causes MCDC1
  • Defective ST3GAL3 causes MCT12 and EIEE15
  • Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
Pathway 2
Drugs 1
  • Ilomastat
Drugs 2
Diseases 1
  • Familial osteochondritis dissecans; Osteochondritis dissecans, short stature, and early-onset osteoarthritis
  • Spondyloepiphyseal dysplasia, Kimberley type
Diseases 2
Novel
Novel
Symbols
IRS2 and EDEM1
Name 1
insulin receptor substrate 2
Name2
ER degradation enhancing alpha-mannosidase like protein 1
Pathway 1
  • PI3K Cascade
  • IRS-mediated signalling
  • SOS-mediated signalling
  • SOS-mediated signalling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • PI3K/AKT activation
  • PI3K/AKT activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • IRS-related events triggered by IGF1R
  • Signaling by Leptin
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • RET signaling
  • Signaling by Erythropoietin
  • Signaling by Erythropoietin
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Growth hormone receptor signaling
Pathway 2
  • XBP1(S) activates chaperone genes
  • ER Quality Control Compartment (ERQC)
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
TNF and TNXB
Name 1
tumor necrosis factor
Name2
tenascin XB
Pathway 1
  • Transcriptional regulation of white adipocyte differentiation
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • TNFR1-induced NF-kappa-B signaling pathway
  • TNFR1-mediated ceramide production
  • TNFR2 non-canonical NF-kB pathway
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • TNF signaling
  • Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells)
Pathway 2
  • ECM proteoglycans
Drugs 1
  • Etanercept
  • Adalimumab
  • Infliximab
  • Chloroquine
  • Epinephrine
  • Pseudoephedrine
  • Clenbuterol
  • Pranlukast
  • Amrinone
  • Trichostatin A
  • Afelimomab
  • YSIL6
  • SD118
  • PN0621
  • OMS-103HP
  • Talmapimod
  • VX-702
  • Atiprimod
  • CRx-139
  • CYT007-TNFQb
  • Andrographolide
  • Ethyl pyruvate
  • AME-527
  • PR-104
  • Plinabulin
  • Dexanabinol
  • Onercept
  • Golimumab
  • Certolizumab pegol
  • Pomalidomide
  • Polaprezinc
  • Foreskin fibroblast (neonatal)
  • Foreskin keratinocyte (neonatal)
  • Bryostatin 1
  • Binimetinib
  • Dilmapimod
  • Glycyrrhizic acid
Drugs 2
Diseases 1
  • Graft-versus-host disease
  • Systemic lupus erythematosus
  • Allograft rejection
  • Asthma
Diseases 2
  • Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
Novel
Novel
Symbols
APC and MAN2A1
Name 1
APC regulator of Wnt signaling pathway
Name2
mannosidase alpha class 2A member 1
Pathway 1
  • Apoptotic cleavage of cellular proteins
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • Deactivation of the beta-catenin transactivating complex
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • CTNNB1 S33 mutants aren't phosphorylated
  • CTNNB1 S37 mutants aren't phosphorylated
  • CTNNB1 S45 mutants aren't phosphorylated
  • CTNNB1 T41 mutants aren't phosphorylated
  • APC truncation mutants are not K63 polyubiquitinated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Ovarian tumor domain proteases
Pathway 2
  • Intra-Golgi traffic
  • Maturation of spike protein
  • Reactions specific to the complex N-glycan synthesis pathway
Drugs 1
Drugs 2
  • Tridolgosir
  • 2-deoxy-2-fluoro-alpha-D-mannosyl fluoride
  • Ghavamiol
  • Kifunensine
  • 5-fluoro-beta-L-gulosyl fluoride
  • 5-Thio-a/B-D-Mannopyranosylamine
  • 1-deoxymannojirimycin
  • (1R,2R,3R,4S,5R)-4-(Benzylamino)-5-(methylthio)cyclopentane-1,2,3-triol
  • (1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol
Diseases 1
  • Cancer of the anal canal
  • Familial adenomatous polyposis
  • Gastric cancer
  • Esophageal cancer
  • Gallbladder cancer
Diseases 2
Novel
Novel
Symbols
TUBG1 and WNT3
Name 1
tubulin gamma 1
Name2
Wnt family member 3
Pathway 1
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • AURKA Activation by TPX2
Pathway 2
  • TCF dependent signaling in response to WNT
  • WNT ligand biogenesis and trafficking
  • WNT ligand biogenesis and trafficking
  • Class B/2 (Secretin family receptors)
Drugs 1
  • Vinblastine
Drugs 2
Diseases 1
Diseases 2
  • Tetra-amelia
Novel
Novel
Symbols
DRD2 and GPC6
Name 1
dopamine receptor D2
Name2
glypican 6
Pathway 1
  • Dopamine receptors
Pathway 2
  • Glycosaminoglycan-protein linkage region biosynthesis
  • HS-GAG biosynthesis
  • HS-GAG biosynthesis
  • HS-GAG degradation
  • Defective B4GALT7 causes EDS, progeroid type
  • Defective B3GAT3 causes JDSSDHD
  • Defective EXT2 causes exostoses 2
  • Defective EXT1 causes exostoses 1, TRPS2 and CHDS
  • Defective B3GALT6 causes EDSP2 and SEMDJL1
  • Attachment and Entry
  • Attachment and Entry
  • Retinoid metabolism and transport
  • Respiratory syncytial virus (RSV) attachment and entry
  • RSV-host interactions
Drugs 1
  • Amphetamine
  • Ziprasidone
  • Cabergoline
  • Ropinirole
  • Dihydroergotamine
  • Olanzapine
  • Clozapine
  • Thiethylperazine
  • Sulpiride
  • Loxapine
  • Remoxipride
  • Pramipexole
  • Promazine
  • Prochlorperazine
  • Droperidol
  • Imipramine
  • Chlorpromazine
  • Buspirone
  • Haloperidol
  • Triflupromazine
  • Nortriptyline
  • Amoxapine
  • Lamotrigine
  • Cinnarizine
  • Lisuride
  • Fluphenazine
  • Thioridazine
  • Ergotamine
  • Apomorphine
  • Paroxetine
  • Trimipramine
  • Risperidone
  • Propiomazine
  • Minaprine
  • Trifluoperazine
  • Perphenazine
  • Flupentixol
  • Amantadine
  • Mesoridazine
  • Maprotiline
  • Dopamine
  • Carphenazine
  • Memantine
  • Ergoloid mesylate
  • Acetophenazine
  • Promethazine
  • Pimozide
  • Desipramine
  • Escitalopram
  • Domperidone
  • Pergolide
  • Bromocriptine
  • Ketamine
  • Quetiapine
  • Metoclopramide
  • Levodopa
  • Aripiprazole
  • Chlorprothixene
  • Paliperidone
  • Yohimbine
  • Methotrimeprazine
  • Alizapride
  • Rolicyclidine
  • Acepromazine
  • Molindone
  • Pipotiazine
  • Thioproperazine
  • Thiothixene
  • Zuclopenthixol
  • Aniracetam
  • Fluspirilene
  • Tetrabenazine
  • Brasofensine
  • Bifeprunox
  • Bicifadine
  • Itopride
  • Iloperidone
  • Rotigotine
  • BL-1020
  • Norclozapine
  • Amitifadine
  • Cariprazine
  • Lumateperone
  • YKP-1358
  • Sertindole
  • Mianserin
  • Asenapine
  • Ocaperidone
  • Amisulpride
  • Sarizotan
  • Sumanirole
  • Nandrolone decanoate
  • Lurasidone
  • Perospirone
  • Bromopride
  • Quinagolide
  • Brexpiprazole
  • Etoperidone
  • AS-8112
  • Blonanserin
  • Melperone
  • Zotepine
  • Pipamperone
  • Dihydro-alpha-ergocryptine
  • Epicriptine
  • Pardoprunox
  • Tetrahydropalmatine
  • Piribedil
  • Raclopride
  • JNJ-37822681
  • Tiapride
  • Dihydroergocristine
  • Aripiprazole lauroxil
Drugs 2
Diseases 1
Diseases 2
  • Heparan sulfate proteoglycan gene defects, including: Dyssegmental dysplasia, Silverman-Handmaker type; Schwartz-Jampel syndrome; Simpson-Golabi-Behmel syndrome, type 1; Omodysplasia 1; Multiple exostoses
Novel
Novel
Symbols
HSPA9 and IL9
Name 1
heat shock protein family A (Hsp70) member 9
Name2
interleukin 9
Pathway 1
  • Mitochondrial protein import
  • Regulation of HSF1-mediated heat shock response
  • Complex I biogenesis
  • Cristae formation
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
  • Mitochondrial protein degradation
  • Mitochondrial unfolded protein response (UPRmt)
  • Complex III assembly
Pathway 2
  • Interleukin-9 signaling
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
PTPRF and ABCG1
Name 1
protein tyrosine phosphatase receptor type F
Name2
ATP binding cassette subfamily G member 1
Pathway 1
  • Receptor-type tyrosine-protein phosphatases
  • Insulin receptor recycling
  • Synaptic adhesion-like molecules
Pathway 2
  • ABC transporters in lipid homeostasis
  • HDL remodeling
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
Drugs 1
Drugs 2
  • ATP
Diseases 1
Diseases 2
Novel
Novel
Symbols
SGCE and SEMA3C
Name 1
sarcoglycan epsilon
Name2
semaphorin 3C
Pathway 1
  • Formation of the dystrophin-glycoprotein complex (DGC)
  • Formation of the dystrophin-glycoprotein complex (DGC)
Pathway 2
Drugs 1
Drugs 2
Diseases 1
  • Primary torsion dystonia (PTD)
Diseases 2
Novel
Novel
Symbols
BBOX1 and ANO3
Name 1
gamma-butyrobetaine hydroxylase 1
Name2
anoctamin 3
Pathway 1
  • Carnitine synthesis
Pathway 2
  • Stimuli-sensing channels
  • Induction of Cell-Cell Fusion
Drugs 1
  • Ascorbic acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
CDK2 and PAX2
Name 1
cyclin dependent kinase 2
Name2
paired box 2
Pathway 1
  • G0 and Early G1
  • Telomere Extension By Telomerase
  • Activation of ATR in response to replication stress
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Processing of DNA double-strand break ends
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • G2 Phase
  • Orc1 removal from chromatin
  • Activation of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates Cell Cycle
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Factors involved in megakaryocyte development and platelet production
Pathway 2
  • Formation of intermediate mesoderm
  • Formation of the nephric duct
  • Formation of the ureteric bud
Drugs 1
  • 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
  • Staurosporine
  • Indirubin-3'-monoxime
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
  • Olomoucine
  • 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide
  • 2-Amino-6-Chloropyrazine
  • 6-O-Cyclohexylmethyl Guanine
  • N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide
  • 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
  • N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
  • Purvalanol
  • [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
  • (5R)-5-{[(2-Amino-3H-purin-6-yl)oxy]methyl}-2-pyrrolidinone
  • 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine
  • Hymenialdisine
  • (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine
  • 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide
  • 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
  • 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
  • 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
  • SU9516
  • 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
  • Alvocidib
  • (2E,3S)-3-hydroxy-5'-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-methyl-1,3-dihydro-2,3'-biindol-2'(1'H)-one
  • 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol
  • 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One
  • Lysine Nz-Carboxylic Acid
  • [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone
  • N'-[4-(2,4-Dimethyl-1,3-thiazol-5-yl)-2-pyrimidinyl]-N-hydroxyimidoformamide
  • N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea
  • 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
  • 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
  • OLOMOUCINE II
  • TRIAZOLOPYRIMIDINE
  • Seliciclib
  • Bosutinib
  • 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
  • (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
  • N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
  • 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
  • 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
  • (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
  • 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE
  • (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine
  • O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE
  • (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide
  • 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
  • N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
  • 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
  • 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
  • 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE
  • (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
  • 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
  • 5-Bromoindirubin
  • (2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (5E)-2-Amino-5-(2-pyridinylmethylene)-1,3-thiazol-4(5H)-one
  • 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
  • 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE
  • N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE
  • (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE
  • 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
  • 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
  • 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE
  • 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA
  • 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • CAN-508
  • (2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE
  • 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
  • (2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol
  • N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
  • 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • RO-4584820
  • N-Methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide
  • N-methyl-{4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide
  • 3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one
  • 4-{[(2-Oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}-N-(1,3-thiazol-2-yl)benzenesulfonamide
  • 3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1H-indole
  • 5-hydroxynaphthalene-1-sulfonamide
  • N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
  • 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
  • N-phenyl-1H-pyrazole-3-carboxamide
  • 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide
  • {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
  • 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE
  • 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide
  • AT-7519
  • 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
  • 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine
  • 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE
  • 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
  • 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE
  • 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
  • (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
  • 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
  • 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE
  • 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE
  • (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
  • 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine
  • 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine
  • N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine
  • 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
  • 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
  • N-(5-Isopropyl-thiazol-2-YL)-2-pyridin-3-YL-acetamide
  • Variolin B
  • N(6)-dimethylallyladenine
  • Trilaciclib
Drugs 2
Diseases 1
Diseases 2
  • Renal coloboma syndrome (RCS); Papillorenal syndrome
Novel
Symbols
BYSL and ETF1
Name 1
bystin like
Name2
eukaryotic translation termination factor 1
Pathway 1
  • Major pathway of rRNA processing in the nucleolus and cytosol
Pathway 2
  • Eukaryotic Translation Termination
  • Eukaryotic Translation Termination
  • Regulation of expression of SLITs and ROBOs
  • Protein hydroxylation
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
CDH1 and CDH5
Name 1
cadherin 1
Name2
cadherin 5
Pathway 1
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Integrin cell surface interactions
  • Apoptotic cleavage of cell adhesion proteins
  • Adherens junctions interactions
  • RHO GTPases activate IQGAPs
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of CDH1 Function
  • Regulation of CDH1 mRNA translation by microRNAs
  • Degradation of CDH1
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Formation of definitive endoderm
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Developmental Lineage of Mammary Stem Cells
Pathway 2
  • Adherens junctions interactions
  • VEGFR2 mediated vascular permeability
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
Drugs 1
Drugs 2
  • Lenalidomide
  • FX06
Diseases 1
  • Penile cancer
  • Breast cancer
  • Gastric cancer
  • Nasopharyngeal cancer
  • Hepatocellular carcinoma
  • Thyroid cancer
Diseases 2
Novel
Symbols
CENPF and IRF6
Name 1
centromere protein F
Name2
interferon regulatory factor 6
Pathway 1
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Polo-like kinase mediated events
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • EML4 and NUDC in mitotic spindle formation
Pathway 2
  • Interferon gamma signaling
  • Interferon alpha/beta signaling
Drugs 1
Drugs 2
Diseases 1
Diseases 2
  • IRF6-related disorders, including: Popliteal pterygium syndrome (PPS); Van der Woude syndrome (VWS)
  • Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
Novel
Symbols
FXR1 and SERINC5
Name 1
FMR1 autosomal homolog 1
Name2
serine incorporator 5
Pathway 1
  • Signaling by BRAF and RAF1 fusions
Pathway 2
  • Serine metabolism
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
HDAC2 and TREML2
Name 1
histone deacetylase 2
Name2
triggering receptor expressed on myeloid cells like 2
Pathway 1
  • p75NTR negatively regulates cell cycle via SC1
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • HDACs deacetylate histones
  • Notch-HLH transcription pathway
  • ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
  • NoRC negatively regulates rRNA expression
  • SUMOylation of chromatin organization proteins
  • Regulation of TP53 Activity through Acetylation
  • RNA Polymerase I Transcription Initiation
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Regulation of MECP2 expression and activity
  • MECP2 regulates neuronal receptors and channels
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • EGR2 and SOX10-mediated initiation of Schwann cell myelination
  • EGR2 and SOX10-mediated initiation of Schwann cell myelination
  • Potential therapeutics for SARS
  • STAT3 nuclear events downstream of ALK signaling
  • Negative Regulation of CDH1 Gene Transcription
  • Factors involved in megakaryocyte development and platelet production
  • Regulation of endogenous retroelements by KRAB-ZFP proteins
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
  • Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)
Pathway 2
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Drugs 1
  • Pravastatin
  • Lovastatin
  • Theophylline
  • Valproic acid
  • Valproic acid
  • Simvastatin
  • Atorvastatin
  • Fluvastatin
  • Aminophylline
  • Decitabine
  • Oxtriphylline
  • Vorinostat
  • Vorinostat
  • Belinostat
  • Pracinostat
  • Romidepsin
  • Romidepsin
  • Panobinostat
  • Phenylbutyric acid
  • Tixocortol
  • Mocetinostat
  • Entinostat
  • Abexinostat
  • Givinostat
  • Pyroxamide
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
FGFR3 and STK32B
Name 1
fibroblast growth factor receptor 3
Name2
serine/threonine kinase 32B
Pathway 1
  • Signaling by activated point mutants of FGFR3
  • t(4;14) translocations of FGFR3
  • Signaling by FGFR3 in disease
  • Signaling by FGFR3 fusions in cancer
Pathway 2
Drugs 1
  • XL999
  • Pazopanib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Infigratinib
  • Fostamatinib
  • Erdafitinib
  • Pemigatinib
  • Futibatinib
  • Selpercatinib
Drugs 2
Diseases 1
  • CATSHL syndrome
  • Multiple myeloma
  • FGFR3-related short limb skeletal dysplasias, including: Achondroplasia; Hypochondroplasia; Thanatophoric dysplasia, type 1; Thanatophoric dysplasia, type 2; Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN)
  • Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome
  • Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
  • Bladder cancer
Diseases 2
Novel
Symbols
CEBPG and CYP26B1
Name 1
CCAAT enhancer binding protein gamma
Name2
cytochrome P450 family 26 subfamily B member 1
Pathway 1
  • ATF4 activates genes in response to endoplasmic reticulum stress
  • Response of EIF2AK4 (GCN2) to amino acid deficiency
  • Response of EIF2AK1 (HRI) to heme deficiency
Pathway 2
  • Vitamins
  • RA biosynthesis pathway
  • Defective CYP26B1 causes RHFCA
Drugs 1
Drugs 2
  • Tretinoin
Diseases 1
Diseases 2
Novel
Symbols
POLR2L and ACSL6
Name 1
RNA polymerase II, I and III subunit L
Name2
acyl-CoA synthetase long chain family member 6
Pathway 1
  • Formation of RNA Pol II elongation complex
  • Formation of the Early Elongation Complex
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
  • HIV Transcription Initiation
  • RNA Polymerase II HIV Promoter Escape
  • Transcription of the HIV genome
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Pausing and recovery of Tat-mediated HIV elongation
  • Abortive elongation of HIV-1 transcript in the absence of Tat
  • Tat-mediated HIV elongation arrest and recovery
  • Tat-mediated elongation of the HIV-1 transcript
  • HIV elongation arrest and recovery
  • Pausing and recovery of HIV elongation
  • Viral Messenger RNA Synthesis
  • Cytosolic sensors of pathogen-associated DNA
  • MicroRNA (miRNA) biogenesis
  • NoRC negatively regulates rRNA expression
  • B-WICH complex positively regulates rRNA expression
  • Transcriptional regulation by small RNAs
  • PIWI-interacting RNA (piRNA) biogenesis
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • RNA Polymerase II Pre-transcription Events
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of DNA Repair Genes
  • FGFR2 alternative splicing
  • RNA polymerase II transcribes snRNA genes
  • RNA polymerase II transcribes snRNA genes
  • mRNA Capping
  • mRNA Splicing - Major Pathway
  • mRNA Splicing - Minor Pathway
  • Processing of Capped Intron-Containing Pre-mRNA
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Transcription Initiation
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase II Promoter Escape
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase III Chain Elongation
  • RNA Polymerase I Transcription Termination
  • RNA Polymerase III Transcription Termination
  • RNA Polymerase III Abortive And Retractive Initiation
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Elongation
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • RNA Polymerase III Transcription Initiation From Type 1 Promoter
  • RNA Polymerase III Transcription Initiation From Type 1 Promoter
  • RNA Polymerase III Transcription Initiation From Type 2 Promoter
  • RNA Polymerase III Transcription Initiation From Type 2 Promoter
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • RNA Pol II CTD phosphorylation and interaction with CE
  • Signaling by FGFR2 IIIa TM
  • Estrogen-dependent gene expression
  • Inhibition of DNA recombination at telomere
Pathway 2
  • Synthesis of very long-chain fatty acyl-CoAs
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
DTNBP1 and BLOC1S3
Name 1
dystrobrevin binding protein 1
Name2
biogenesis of lysosomal organelles complex 1 subunit 3
Pathway 1
  • Golgi Associated Vesicle Biogenesis
Pathway 2
  • Golgi Associated Vesicle Biogenesis
Drugs 1
Drugs 2
Diseases 1
  • Hermansky-Pudlak syndrome (HPS)
Diseases 2
  • Hermansky-Pudlak syndrome (HPS)
Novel
Symbols
ACAN and SLCO3A1
Name 1
aggrecan
Name2
solute carrier organic anion transporter family member 3A1
Pathway 1
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Keratan sulfate biosynthesis
  • Keratan sulfate degradation
  • ECM proteoglycans
  • Defective CHST6 causes MCDC1
  • Defective ST3GAL3 causes MCT12 and EIEE15
  • Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
Pathway 2
Drugs 1
  • Ilomastat
Drugs 2
Diseases 1
  • Familial osteochondritis dissecans; Osteochondritis dissecans, short stature, and early-onset osteoarthritis
  • Spondyloepiphyseal dysplasia, Kimberley type
Diseases 2
Novel
Symbols
IRS2 and EDEM1
Name 1
insulin receptor substrate 2
Name2
ER degradation enhancing alpha-mannosidase like protein 1
Pathway 1
  • PI3K Cascade
  • IRS-mediated signalling
  • SOS-mediated signalling
  • SOS-mediated signalling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • PI3K/AKT activation
  • PI3K/AKT activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • IRS-related events triggered by IGF1R
  • Signaling by Leptin
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • RET signaling
  • Signaling by Erythropoietin
  • Signaling by Erythropoietin
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Growth hormone receptor signaling
Pathway 2
  • XBP1(S) activates chaperone genes
  • ER Quality Control Compartment (ERQC)
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
TNF and TNXB
Name 1
tumor necrosis factor
Name2
tenascin XB
Pathway 1
  • Transcriptional regulation of white adipocyte differentiation
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • TNFR1-induced NF-kappa-B signaling pathway
  • TNFR1-mediated ceramide production
  • TNFR2 non-canonical NF-kB pathway
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • TNF signaling
  • Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells)
Pathway 2
  • ECM proteoglycans
Drugs 1
  • Etanercept
  • Adalimumab
  • Infliximab
  • Chloroquine
  • Epinephrine
  • Pseudoephedrine
  • Clenbuterol
  • Pranlukast
  • Amrinone
  • Trichostatin A
  • Afelimomab
  • YSIL6
  • SD118
  • PN0621
  • OMS-103HP
  • Talmapimod
  • VX-702
  • Atiprimod
  • CRx-139
  • CYT007-TNFQb
  • Andrographolide
  • Ethyl pyruvate
  • AME-527
  • PR-104
  • Plinabulin
  • Dexanabinol
  • Onercept
  • Golimumab
  • Certolizumab pegol
  • Pomalidomide
  • Polaprezinc
  • Foreskin fibroblast (neonatal)
  • Foreskin keratinocyte (neonatal)
  • Bryostatin 1
  • Binimetinib
  • Dilmapimod
  • Glycyrrhizic acid
Drugs 2
Diseases 1
  • Graft-versus-host disease
  • Systemic lupus erythematosus
  • Allograft rejection
  • Asthma
Diseases 2
  • Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
Novel
Symbols
APC and MAN2A1
Name 1
APC regulator of Wnt signaling pathway
Name2
mannosidase alpha class 2A member 1
Pathway 1
  • Apoptotic cleavage of cellular proteins
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • Deactivation of the beta-catenin transactivating complex
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • CTNNB1 S33 mutants aren't phosphorylated
  • CTNNB1 S37 mutants aren't phosphorylated
  • CTNNB1 S45 mutants aren't phosphorylated
  • CTNNB1 T41 mutants aren't phosphorylated
  • APC truncation mutants are not K63 polyubiquitinated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Ovarian tumor domain proteases
Pathway 2
  • Intra-Golgi traffic
  • Maturation of spike protein
  • Reactions specific to the complex N-glycan synthesis pathway
Drugs 1
Drugs 2
  • Tridolgosir
  • 2-deoxy-2-fluoro-alpha-D-mannosyl fluoride
  • Ghavamiol
  • Kifunensine
  • 5-fluoro-beta-L-gulosyl fluoride
  • 5-Thio-a/B-D-Mannopyranosylamine
  • 1-deoxymannojirimycin
  • (1R,2R,3R,4S,5R)-4-(Benzylamino)-5-(methylthio)cyclopentane-1,2,3-triol
  • (1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol
Diseases 1
  • Cancer of the anal canal
  • Familial adenomatous polyposis
  • Gastric cancer
  • Esophageal cancer
  • Gallbladder cancer
Diseases 2
Novel
Symbols
TUBG1 and WNT3
Name 1
tubulin gamma 1
Name2
Wnt family member 3
Pathway 1
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • AURKA Activation by TPX2
Pathway 2
  • TCF dependent signaling in response to WNT
  • WNT ligand biogenesis and trafficking
  • WNT ligand biogenesis and trafficking
  • Class B/2 (Secretin family receptors)
Drugs 1
  • Vinblastine
Drugs 2
Diseases 1
Diseases 2
  • Tetra-amelia
Novel
Symbols
DRD2 and GPC6
Name 1
dopamine receptor D2
Name2
glypican 6
Pathway 1
  • Dopamine receptors
Pathway 2
  • Glycosaminoglycan-protein linkage region biosynthesis
  • HS-GAG biosynthesis
  • HS-GAG biosynthesis
  • HS-GAG degradation
  • Defective B4GALT7 causes EDS, progeroid type
  • Defective B3GAT3 causes JDSSDHD
  • Defective EXT2 causes exostoses 2
  • Defective EXT1 causes exostoses 1, TRPS2 and CHDS
  • Defective B3GALT6 causes EDSP2 and SEMDJL1
  • Attachment and Entry
  • Attachment and Entry
  • Retinoid metabolism and transport
  • Respiratory syncytial virus (RSV) attachment and entry
  • RSV-host interactions
Drugs 1
  • Amphetamine
  • Ziprasidone
  • Cabergoline
  • Ropinirole
  • Dihydroergotamine
  • Olanzapine
  • Clozapine
  • Thiethylperazine
  • Sulpiride
  • Loxapine
  • Remoxipride
  • Pramipexole
  • Promazine
  • Prochlorperazine
  • Droperidol
  • Imipramine
  • Chlorpromazine
  • Buspirone
  • Haloperidol
  • Triflupromazine
  • Nortriptyline
  • Amoxapine
  • Lamotrigine
  • Cinnarizine
  • Lisuride
  • Fluphenazine
  • Thioridazine
  • Ergotamine
  • Apomorphine
  • Paroxetine
  • Trimipramine
  • Risperidone
  • Propiomazine
  • Minaprine
  • Trifluoperazine
  • Perphenazine
  • Flupentixol
  • Amantadine
  • Mesoridazine
  • Maprotiline
  • Dopamine
  • Carphenazine
  • Memantine
  • Ergoloid mesylate
  • Acetophenazine
  • Promethazine
  • Pimozide
  • Desipramine
  • Escitalopram
  • Domperidone
  • Pergolide
  • Bromocriptine
  • Ketamine
  • Quetiapine
  • Metoclopramide
  • Levodopa
  • Aripiprazole
  • Chlorprothixene
  • Paliperidone
  • Yohimbine
  • Methotrimeprazine
  • Alizapride
  • Rolicyclidine
  • Acepromazine
  • Molindone
  • Pipotiazine
  • Thioproperazine
  • Thiothixene
  • Zuclopenthixol
  • Aniracetam
  • Fluspirilene
  • Tetrabenazine
  • Brasofensine
  • Bifeprunox
  • Bicifadine
  • Itopride
  • Iloperidone
  • Rotigotine
  • BL-1020
  • Norclozapine
  • Amitifadine
  • Cariprazine
  • Lumateperone
  • YKP-1358
  • Sertindole
  • Mianserin
  • Asenapine
  • Ocaperidone
  • Amisulpride
  • Sarizotan
  • Sumanirole
  • Nandrolone decanoate
  • Lurasidone
  • Perospirone
  • Bromopride
  • Quinagolide
  • Brexpiprazole
  • Etoperidone
  • AS-8112
  • Blonanserin
  • Melperone
  • Zotepine
  • Pipamperone
  • Dihydro-alpha-ergocryptine
  • Epicriptine
  • Pardoprunox
  • Tetrahydropalmatine
  • Piribedil
  • Raclopride
  • JNJ-37822681
  • Tiapride
  • Dihydroergocristine
  • Aripiprazole lauroxil
Drugs 2
Diseases 1
Diseases 2
  • Heparan sulfate proteoglycan gene defects, including: Dyssegmental dysplasia, Silverman-Handmaker type; Schwartz-Jampel syndrome; Simpson-Golabi-Behmel syndrome, type 1; Omodysplasia 1; Multiple exostoses
Novel
Symbols
HSPA9 and IL9
Name 1
heat shock protein family A (Hsp70) member 9
Name2
interleukin 9
Pathway 1
  • Mitochondrial protein import
  • Regulation of HSF1-mediated heat shock response
  • Complex I biogenesis
  • Cristae formation
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
  • Mitochondrial protein degradation
  • Mitochondrial unfolded protein response (UPRmt)
  • Complex III assembly
Pathway 2
  • Interleukin-9 signaling
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
PTPRF and ABCG1
Name 1
protein tyrosine phosphatase receptor type F
Name2
ATP binding cassette subfamily G member 1
Pathway 1
  • Receptor-type tyrosine-protein phosphatases
  • Insulin receptor recycling
  • Synaptic adhesion-like molecules
Pathway 2
  • ABC transporters in lipid homeostasis
  • HDL remodeling
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
Drugs 1
Drugs 2
  • ATP
Diseases 1
Diseases 2
Novel
Symbols
SGCE and SEMA3C
Name 1
sarcoglycan epsilon
Name2
semaphorin 3C
Pathway 1
  • Formation of the dystrophin-glycoprotein complex (DGC)
  • Formation of the dystrophin-glycoprotein complex (DGC)
Pathway 2
Drugs 1
Drugs 2
Diseases 1
  • Primary torsion dystonia (PTD)
Diseases 2
Novel
Symbols
BBOX1 and ANO3
Name 1
gamma-butyrobetaine hydroxylase 1
Name2
anoctamin 3
Pathway 1
  • Carnitine synthesis
Pathway 2
  • Stimuli-sensing channels
  • Induction of Cell-Cell Fusion
Drugs 1
  • Ascorbic acid
Drugs 2
Diseases 1
Diseases 2

Page 1 out of 28 pages

© Madhavi K. Ganapathiraju 2012-2025